KWM
JAZZ icon

Kiker Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kiker Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$106 – 442
2025
Q2 		$106 Hold
1
– – ﹤0.01% 596
2025
Q1 		$124 Buy
+1
New +$130 ﹤0.01% 686

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Kiker Wealth Management's JAZZ Position: Q3 2025 in Review

Kiker Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 1 share — an estimated $106 sold.

Kiker Wealth Management first reported a position in JAZZ in Q1 2025 and held it in 2 quarters. The position peaked at $124 in Q1 2025. 503 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

  • Kiker Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Kiker Wealth Management sold 1 Jazz Pharmaceuticals share in Q3 2025, an estimated $106.
  • Kiker Wealth Management first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Kiker Wealth Management's Jazz Pharmaceuticals position peaked at $124 in Q1 2025.
  • 503 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Kiker Wealth Management's 13F filing for Q3 2025, filed 27 Oct 2025.